Miltonian Fc Tab (Ticagrelor)

Ticagrelor, the active ingredient in Miltonian Fc Tab, is a P2Y12 receptor antagonist presented as a tablet for oral use. It treats acute coronary syndrome, myocardial infarction and is used to prevent stroke in patients with ACS.

GNH USA supplies Miltonian Fc Tab as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ticagrelor is indicated for antiplatelet therapy in several cardiovascular conditions.

- Acute coronary syndrome: reduces the risk of cardiovascular death, myocardial infarction and stroke. - Myocardial infarction: prevents recurrent ischemic events after an acute event. - Stroke prevention in ACS: lowers the incidence of stroke in patients with acute coronary syndrome.

Ticagrelor may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dyspnea: shortness of breath, often mild to moderate. - Headache: transient and usually self‑limiting. - Nausea or dyspepsia: gastrointestinal discomfort. - Diarrhea: loose stools without severe dehydration. - Increased bleeding tendency: minor bruising or gum bleeding. - Elevated serum uric acid: may be noted in laboratory tests.

Serious or Rare Side Effects: - Major hemorrhage: intracranial or gastrointestinal bleeding requiring medical intervention. - Severe allergic reactions: anaphylaxis or angioedema. - Bradyarrhythmias: marked slowing of heart rate, especially in patients with pre‑existing conduction disorders.

Before prescribing Miltonian Fc Tab, clinicians should consider several safety aspects.

- Bleeding risk: monitor patients for signs of major or minor bleeding. - Dyspnea: assess any new shortness of breath and adjust therapy if needed. - Bradyarrhythmias: watch for slow heart rates, particularly in those with conduction disorders. - Hepatic impairment: use with caution in severe liver disease. - Drug interactions: avoid concomitant strong CYP3A4 inhibitors. - Store at ambient temperature: keep below 25 °C, retain in the original pack and protect from moisture.

Ticagrelor interacts with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase ticagrelor plasma levels and bleeding risk. - P‑gp inhibitors (e.g., verapamil): can raise exposure and heighten bleeding tendency.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce ticagrelor efficacy. - NSAIDs or anticoagulants (e.g., warfarin): increase overall bleeding risk. - Statins metabolized by CYP3A4 (e.g., simvastatin): may require dose adjustment to avoid toxicity.